CLB used as the standard drug for CLL patients for many years, now is often replaced by the targeted drugs, with the leading role of venetoclax, the BCL2 inhibitor [1,2,3,4,16]. This evidence concerns the gene CLYBL and B-cell chronic lymphocytic leukemia.